Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
TARS
#1666
Tarsus Pharmaceuticals, Inc. Common Stock
72.500
0
USD
-0.21%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
-0.21%
Changement Mensuel
+5.82%
Evolution sur 6 mois
+9.75%
Changement Annuel
+9.75%
Clôture Précédente
72.650
0
Open
72.485
0
Bid
Ask
Low
72.485
0
High
73.150
0
Volume
33
Marchés
Actions des Marchés US
Soins de Santé
TARS
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
20.5 M
20.71 M
26.73 M
34.22 M
38.38 M
42.56 M
—
Valuation ratios
Enterprise value
679.26 M
294.62 M
334.13 M
496.64 M
2.1 B
3.38 B
9.62 B
Price to earnings ratio
—
-33.58
-5.72
-4.36
-18.04
-51.5
-118
Price to sales ratio
—
8.11
13.75
33.95
11.38
7.58
28.09
Price to cash flow ratio
—
123.39
-7.24
-5.04
-25.08
-274.78
-367.61
Price to book ratio
—
2.77
1.84
3.01
9.27
9.96
15.19
Enterprise value to EBITDA ratio
-25.34
-25.52
-4.97
-3.2
-16.5
-44.58
-104.72
Profitability ratios
Return on assets %
-0.16
-0.08
-0.27
-0.51
-0.31
-0.12
-0.13
Return on equity %
-0.16
-0.08
-0.32
-0.69
-0.51
-0.19
-0.2
Return on invested capital %
-1 906.71
-566.25
-2 112.36
-2 838.11
-1 840.82
-617.61
—
Gross margin %
—
100
100
100
100
100
400
Operating margin %
—
-21.32
-242.92
-820.53
-65.9
-15.72
-72.66
EBITDA margin %
—
-20.24
-244.4
-831.43
-67.27
-16.4
-75.25
Net margin %
—
-24.25
-240.51
-778.89
-63.16
-14.72
-68
Liquidity ratios
Quick ratio
—
—
—
6.85
4.39
3.82
18.83
Current ratio
31.68
15.33
14.61
6.93
4.42
3.85
18.97
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0
0.33
0.13
0.07
0.57
0.96
0.89
Solvency ratios
Debt to assets ratio
—
—
0.09
0.12
0.19
0.15
0.59
Debt to equity ratio
—
—
0.11
0.16
0.32
0.24
0.92
Long term debt to total assets ratio
—
—
0.09
0.11
0.19
0.13
0.55
Long term debt to total equity ratio
—
—
0.1
0.15
0.32
0.21
0.85
Per share metrics
Operating cash flow per share
—
0.18
-1.99
-4
-2.21
-0.3
-0.33
EBIT per share
—
-0.59
-2.55
-4.87
-3.21
-1.7
-1.72
EBITDA per share
—
-0.56
-2.56
-4.94
-3.27
-1.77
-1.78
Total debt per share
—
—
0.83
1.08
1.93
1.99
7.47
Cash per share
—
8.36
8.82
7.74
7.75
9.99
38.78
Net current asset value per share
—
8.56
9.15
8.72
9.49
12.51
47.71
Tangible book value per share
—
8.11
7.84
6.57
5.75
8.04
31.89
Working capital per share
—
8
8.53
7.46
7.34
9.26
37.39
Book value per share
—
8.11
7.84
6.7
5.97
8.22
32.64
Nouvelles
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses (NASDAQ:TARS)
Gold Stocks, AI Leader Broadcom Among 25 Newcomers To Best Stock Lists
Tarsus administre le premier patient dans un essai de prévention de la maladie de Lyme
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
Mizuho relève l’objectif de cours de Tarsus Pharmaceuticals après l’approbation en Chine
William Blair réitère sa recommandation Surperformance sur Tarsus Pharmaceuticals
Les actions de Tarsus Pharmaceuticals progressent après l’approbation du médicament en Chine
Tarsus perçoit 15 millions $ suite à l’approbation en Chine
Cloudflare Qualifies For Two Top Stock Lists, Leads 13 Newcomers To IBD 50, Stock Spotlight, More
Tarsus Pharmaceuticals à la conférence Barclays : croissance stratégique et défis
Tarsus Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges
Le COO de Tarsus Pharma Neervannan Seshadri vend pour 641.000$ d’actions